ArticleJournal of chemical information and modeling2024
PandaOmics: An AI-Driven Platform for Therapeutic Target and Biomarker Discovery.
Article in Journal of chemical information and modeling, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed.
- A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial.Nature medicine · 2025Trial
- Combating antimicrobial resistance through multimodal data via artificial intelligence.One health (Amsterdam, Netherlands) · 2026Review
- Integration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment.Nature biotechnology · 2026Article
- New thinking for the next generation of antimalarials.EMBO molecular medicine · 2026Review
- Multi-omics-driven precision medicine.iMeta · 2026Review
- A combined artificial intelligence-wet lab approach identifies a pivotal role of the NADAlzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Target identification and assessment in the era of AI.Nature reviews. Drug discovery · 2026Review
- Target discovery and drug design in the era of artificial intelligence.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Review
- Advancing target discovery through disease-specific integration of multi-modal target identification models and comprehensive benchmarking system.Scientific reports · 2026Article
- From Prompt to Drug: Toward Pharmaceutical Superintelligence.ACS central science · 2026Review
- Genomics of drug target prioritization for complex diseases.Nature reviews. Genetics · 2026Review
- AI accelerate the identification of druggable targets by 3D structures of proteins and compounds.NPJ precision oncology · 2026Review
- Integrative Genomic and AI Approaches to Lung Cancer and Implications for Disease Prevention in Former Smokers.International journal of molecular sciences · 2026Review
- Machine Learning Application in Enhancing HIV Management and Treatment Outcomes: Revolutionizing HIV Infection.Current HIV research · 2026Review
- Research Hotspots and Emerging Trends in Osteoporosis Epigenetics.Genetics research · 2026Article
- Immunotherapy drug target identification using machine learning and patient-derived tumour explant validation.Nature machine intelligence · 2026Article
- Integrated AHP-Delphi and Mini-HTA for selection of metabolic drugs in China's national medical insurance catalog: a framework towards quantitative dynamic adjustment.Journal of pharmaceutical policy and practice · 2026Article
- AI-aided identification of dual-purpose therapeutic targets PRPF19 and MAPK9 in hepatocellular carcinoma and cellular senescence.npj aging · 2025Article
- Exploiting artificial intelligence in precision oncology: an updated comprehensive review.Journal of translational medicine · 2025Review
- Temporal trends in evidence supporting novel drug target discovery.Nature communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PandaOmics is a cloud-based software platform that applies artificial intelligence and bioinformatics techniques to multimodal omics and biomedical text data for therapeutic target and biomarker discovery. PandaOmics generates novel and repurposed therapeutic target and biomarker hypotheses with the desired properties and is available through licensing or collaboration. Targets and biomarkers generated by the platform were previously validated in both
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.